NovoLog FlexTouch Pen
Fiasp Flex Touch
Insulin Aspart
Select product strength & quantity:

Prescription Required.

Product of Canada.

Shipped from Canada.

Prescription Required.Product of Canada.Shipped from Canada.

NovoLog FlexTouch Pen

What is NovoLog FlexTouch Pen?

NovoLog FlexTouch Pen is a prefilled pen that contains NovoLog (insulin aspart). Insulin aspart is a man-made insulin used to control high blood sugar in patients with diabetes mellitus.

How does Novolog FlexTouch Pen work?

The primary activity of NovoLog is glucose metabolism regulation. Insulins, including insulin aspart, exert their action by binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating the cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting the output of glucose from the liver.

Dosage and How to Use

NovoLog FlexTouch Pens are only available as 100 units of insulin aspart per ml (U-100) in 3 ml pens.

General dosing information

  • NovoLog insulin dosing must be individualized.
  • NovoLog has an earlier onset of action than regular human insulin.
  • NovoLog FlexTouch Pen is given subcutaneously and should generally be given in combination with an intermediate or long-acting insulin.

Important administration information

  • Do not use NovoLog if it is viscous or cloudy; only use it if it is clear and colorless.
  • Never use NovoLog beyond its expiration date.

Subcutaneous injection

  • NovoLog FlexTouch Pen should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm.
  • NovoLog should be injected immediately (within 5-10 minutes) before a meal.
  • Injection sites should be rotated within the same region to reduce the risk of lipodystrophy.

Storage

NovoLog FlexTouch Pens should not be exposed to excessive heat or sunlight.

Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze NovoLog, and do not use NovoLog if it has been frozen.

Keep unused NovoLog FlexTouch Pens in the carton so they will stay clean and protected from light.

Summary of Storage for NovoLog FlexTouch Pen

Not in-use (unopened) Room Temperature (below 30°C)Not in-use (unopened) RefrigeratedIn-use (opened) Room Temperature (below 30°C)
3 mL NovoLog FlexTouch Pens28 daysUntil expiration date28 days (Do not refrigerate)

Overdosage

Mild overdose of insulin can result in hypoglycemia and hypokalemia. Mild hypoglycemia can be treated with oral glucose. If you have severely overdosed your insulin, seek medical attention immediately, as more severe episodes of hypoglycemia can lead to coma, seizures, or neurological impairment. Severe hypoglycemia can be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Hypokalemia must be corrected appropriately.

Side Effects

Common side effects of NovoLog FlexTouch Pen may include:

  • Reactions at the injection site
  • Itching and rash
  • Skin thickening or pits at the injection site (lipodystrophy)
  • Weight gain
  • Swelling of the hands and feet

Serious side effects that are possible with NovoLog FlexTouch Pen are:

  • Hypoglycemia
    • Signs of hypoglycemia may include:
      •  Light-headedness
      •  Dizziness
      •  Confusion
      •  Blurred vision
      •  Shakiness
      •  Anxiety or mood changes
      •  Hunger
  • Hypokalemia
  • Serious allergic reactions
    • Seek medical attention immediately if you have any one of the following signs of a severe allergic reaction:
      • Rash over your whole body
      • Trouble breathing
      • Fast heartbeat
      • Swelling of your face, tongue, or throat
      • Sweating
      • Extreme drowsiness

Warnings & Precautions

Never Share a NovoLog FlexTouch Pen between Patients

  • FlexTouch Pens should never be shared, even if the needle is changed. Sharing poses a risk for the transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

  • Changes in insulin, insulin strength, manufacturer, type, or method of administration may affect glycemic control. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia. A sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia.

Hypoglycemia

  • Hypoglycemia is the most common adverse reaction of all insulin therapies. Severe hypoglycemia can lead to seizures, unconsciousness, and even death. Patients at higher risk for hypoglycemia or who have reduced symptomatic awareness of hypoglycemia may need to monitor blood glucose more frequently.

Hypoglycemia Due to Medication Errors

  • Accidental mix-ups between insulin products have been reported. Instruct patients to always check the insulin label before each injection to minimize medication errors.

Hypersensitivity Reactions

  • Severe, life-threatening, generalized allergies, including anaphylaxis, can occur with insulin products.

Hypokalemia

  • All insulin products can cause a shift of potassium from the extracellular space to the intracellular space, potentially leading to hypokalemia. Untreated hypokalemia can lead to respiratory paralysis, ventricular arrhythmia, and death.

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonist

  • Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)­ gamma agonists and can cause fluid retention, particularly when used in combination with insulin. Fluid retention can lead to heart failure or exacerbate existing heart failure.

This is not a comprehensive list of all the possible side effects of NovoLog FlexTouch Pen. Please reach out to your doctor or pharmacist for more information.

Drug Interactions and Other Interactions

Drugs That May Increase the Risk of Hypoglycemia

  • Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics

Drugs That May Decrease the Blood Glucose Lowering Effect of NovoLog

  • Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of NovoLog

  • Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia

Drugs That May Blunt Signs and Symptoms of Hypoglycemia

  • Beta-blockers, clonidine, guanethidine, and reserpine

Contraindications

NovoLog is contraindicated in any of the following:

  • During episodes of hypoglycemia
  • In patients with known hypersensitivity to insulin aspart or one of the excipients in NovoLog FlexTouch Pen

Frequently Asked Questions

NovoLog FlexTouch Pen is a prefilled pen that contains NovoLog (insulin aspart). Insulin aspart is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.

Insulins, including NovoLog, bind to insulin receptors and lower blood sugar by transferring glucose in the blood into muscle and fat cells. Insulin also inhibits the output of glucose from the liver.

You should not take NovoLog if you are having an episode of low blood sugar (hypoglycemia) or are allergic to insulin aspart or any ingredient in NovoLog.

Always take NovoLog exactly as instructed by your doctor because the directions may change until your blood sugar is well controlled.

NovoLog begins to work very quickly. Make sure to start eating a meal 5-10 minutes after taking a dose. Know the type and strength of insulin you are taking, and never change the type of insulin unless instructed by your healthcare provider.

Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels.

Do not reuse or share needles with other people. You may give others a serious infection or get a serious infection from them.

If you have just started taking NovoLog, avoid driving or operating heavy machinery until you know how it affects you. Avoid consuming alcohol or using medications that contain alcohol.

The most common side effects of NovoLog FlexTouch Pen may include:

  • Reactions at the injection site
  • Itching and rash
  • Skin thickening or pits at the injection site (lipodystrophy)
  • Weight gain
  • Swelling of the hands and feet

This is not a comprehensive list of all the possible side effects of NovoLog. Please reach out to your doctor or pharmacist for more information.

Potential serious side effects of NovoLog FlexTouch Pen include:

  • Low blood sugar
    • Symptoms of low blood sugar may include:
      • Light-headedness
      • Dizziness
      • Confusion
      • Blurred vision
      • Shakiness
      • Anxiety or mood changes
      • Hunger
  • Low potassium in your blood
  • Serious allergic reactions
    • Seek medical attention immediately if you have any of the following signs of a severe allergic reaction:
      • Rash over your whole body
      • Trouble breathing
      • Fast heartbeat
      • Swelling of your face, tongue, or throat
      • Sweating
      • Extreme drowsiness

This is not a comprehensive list of all the possible side effects of NovoLog. Please reach out to your doctor or pharmacist for more information.

The active ingredient in NovoLog FlexTouch Pen is insulin aspart, and the inactive ingredients include glycerin, phenol, metacresol, zinc, disodium hydrogen phosphate dihydrate, sodium chloride, and water for injection.

  • Store unused NovoLog FlexTouch Pens in the refrigerator at 36°F to 46°F (2°C to 8°C)
  • Store the pen you are currently using at room temperature (not in the refrigerator) below 86°F.
  • Do not freeze NovoLog. Do not use NovoLog if it has been frozen.
  • Keep NovoLog away from heat or light.
  • Unused pens may be used until the expiration date printed on the label if kept in the refrigerator.
  • The NovoLog FlexTouch pen you are using should be thrown away after 28 days, even if it still has insulin left in it.

Make sure to tell your healthcare provider about all your medical conditions. Inform them immediately if you become pregnant are plan on becoming pregnant. Inform your doctor about all the medications you are taking, including prescription, over-the-counter, vitamins, and natural supplements.

If you miss a dose of NovoLog, check your blood sugar levels to decide if an insulin dose is needed. Your doctor will have more information about the blood sugar ranges that are specific to you. Continue with your regular dosing schedule at the next meal.

Many medications can interact with NovoLog. Ensure that your doctor knows all the medications you are taking, including prescription, over-the-counter, natural supplements, and vitamins.

A mild overdose of insulin can result in hypoglycemia and can be treated with oral glucose. If you have severely overdosed your insulin, seek medical attention immediately, as more severe episodes of hypoglycemia can lead to coma, seizures, or neurological impairment. Symptoms of severe hypoglycemia can include drowsiness, confusion, blurred vision, weakness, and loss of consciousness.

NovoLog works quickly. The effects can usually be seen about 15 minutes after injection.

Never use NovoLog if it looks cloudy or discolored. Only use NovoLog if the solution appears clear and colorless.

NovoLog FlexTouch Pens or Novolog products are not interchangeable with Fiasp. Never change insulins unless instructed by your doctor. With that said, NovoLog and Fiasp both contain the active ingredient insulin aspart, but they are not the same.